Navigation Links
Personal Health Technology Spending to Exceed $460 Million in the Disease Management Sector in 2013
Date:2/17/2009

Competitive pressure and congressional stimulus funds drive adoption

DALLAS, Feb. 17 /PRNewswire/ -- Providers of personal health technologies such as health monitoring devices and personal health records (PHR) can generate over $460 million in revenue in 2013 by targeting the disease management (DM) industry, according to Parks Associates' recent report Disease Management Industry and High-Tech Adoption. The international research firm cites changes in the healthcare landscape, combined with the Obama administration's stimulus package and reform initiatives, as catalysts for accelerated technology spending over the next five years.

"The drumbeat grows louder each day demanding transformation of our healthcare system," said Harry Wang, Director of Health and Mobile Product Research, Parks Associates. "The DM sector is subject to the same pressure and must act quickly or risk obsolescence in the face of competing care management models."

Wang says technology vendors that are familiar with the unique characteristics of the DM business and can show the clear and immediate benefits of their solution within this context will be in the best position to win these contracts.

"Personal technologies such as home health diagnostic and monitoring devices, PHR, and Web and mobile communication applications will become competitive advantages for a new breed of DM companies," Wang said. "These tools will make DM services more effective and efficient, benefiting everyone from patients to payers."

Disease Management Industry and High-Tech Adoption is Parks Associates' latest research report about the future of the disease management industry. It highlights challenges and opportunities and discusses technology's role in driving innovations in new care management models.

For additional information, visit http://www.parksassociates.com or contact 972-490-1113 or sales@parksassociates.com.

About Parks Associates: Parks Associates is an internationally recognized market research and consulting company specializing in emerging consumer technology products and services. Founded in 1986, Parks Associates creates research capital for companies ranging from Fortune 500 to small start-ups through market reports, primary studies, consumer research, custom research, workshops, executive conferences, and annual service subscriptions.

Each year, Parks Associates hosts executive thought leadership conferences CONNECTIONS(TM), with support from the Consumer Electronics Association (CEA(R)), and CONNECTIONS(TM) Europe. In addition, Parks Associates produces the online publication Industry Insights in conjunction with the CONNECTIONS(TM) Conference series.

http://www.parksassociates.com | http://www.connectionsconference.com | http://www.connectionseurope.com | http://www.connectionsindustryinsights.com

    Contact: Mindi Sue Sternblitz-Rubenstein
    Parks Associates
    972-490-1113
    Email: mindi.sue@parksassociates.com


'/>"/>
SOURCE Parks Associates
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Desire for Performance Coupled With Natural Ingredients Boosts Botanical Actives Consumption in Personal Care
2. Crossover Health Launches Personal Health Advisory Service
3. Final Economic Stimulus Bill Permits Americans Personal Health Information to Be Sold for Research and Public Health Purposes WITHOUT Patients Consent
4. MIT project uses personal digital assistants to track TB data
5. Leading UK Personal Trainer Challenges Standards of Service Within Fitness Industry to Get Results or Double Your Money Back Guarantee
6. New genomic test can personalize breast cancer treatment
7. User Centric Develops Guidelines for Personal Health Record (PHR) Applications Based on User Research
8. UCLA scientists develop crystal ball for personalized cancer treatment
9. AutoGenomics CYP 2C19 Test Used in Study to Personalize Clopidogrel (Plavix) Dosing in Patients
10. Personal disaster preparedness
11. January 2009 Mayo Clinic Womens HealthSource Highlights Stroke Symptoms, Personal Health Records and Volunteering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... February 26, 2017 , ... ODH, Inc.™ announced today it will exhibit ... Sheraton Pentagon City Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, ... to improve Medicaid population health management. , ODH will also have an exhibit booth ...
(Date:2/25/2017)... ... February 25, 2017 , ... FCPX users now have the ability to ... Studios. With ProSharpen Color users have total control over sharpening amount, sharpening radius, threshold, ... With color spectrum tools users can visually see the color range effected with ease ...
(Date:2/24/2017)... ... ... Only two months after the official release of The Private Collection – Edition 2017 ... initiated a second print-run of its lavish luxury travel coffee table book. , ... in at more than six kilos, retails at EUR 1,000 per copy and is ...
(Date:2/24/2017)... ... , ... Dr. Ronald E. Hawkins, vice president for academic ... A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean of ... comes to Liberty from the Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... and hearing disabilities, it is so critically important that we all are aware ... That is why Mediaplanet is proud to announce the launch of its newest ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une société de ... excellents résultats semestriels clos le 31 décembre 2016 par ... « Résultats et mise à jour sur la croissance biomédicale ... Faits marquants Bénéfice ... hausse de 104 %) Bénéfice par action ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
Breaking Medicine Technology: